Value in Neurology
Alemtuzumab Most Cost-Effective Multiple Sclerosis Treatment for Achieving No Evidence of Disease Activity
A cost-effectiveness analysis of relapsing-remitting multiple sclerosis (MS) therapies has shown the importance of using first-line treatments first to treat the disease. In terms of achieving no evidence of disease activity (NEDA), the most effective treatment strategy was natalizumab in the first-line setting, followed by alemtuzumab as first-line treatment, according to a presentation at the 2016 American Academy of Neurology annual meeting.
Results 1 - 3 of 3